Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE
Parliamentary submission

DATE
2016-10-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana

https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legislation, Regulation and Restriction of Access to Marijuana

Government of Canada - Task Force on Marijuana Legalization and Regulation

August 25, 2016

STATEMENT / DÉCLARATION

In terms of the Canadian Medical Association's (CMA) mission and values, the legalization of marijuana is a significant issue that requires careful consideration. The CMA supports evidence-based policies that prioritize public health and safety, and we believe that the government should consider the following key points:

1. Public Health and Safety: The health risks associated with marijuana use should be thoroughly assessed and communicated to the public. The government should establish clear guidelines for the safe consumption of marijuana and ensure that proper education and awareness programs are in place.

2. Evidence-Based Regulation: The government should develop comprehensive regulations that take into account the latest scientific research on marijuana. These regulations should aim to minimize the risks associated with marijuana use while ensuring that patients with medical conditions who rely on marijuana for relief are not unduly affected.

3. Controlled Distribution: The government should establish a controlled distribution system that prioritizes the safety and convenience of patients. This system should ensure that marijuana is available only through licensed retailers, and that there are adequate measures in place to prevent diversion and misuse.

4. Public Education: The government should invest in public education campaigns that inform the public about the potential health risks and benefits associated with marijuana use. These campaigns should be backed by accurate and up-to-date information from credible sources.

5. International Comparisons: The government should study the experiences of other countries that have legalized marijuana to identify best practices and potential areas for improvement.

We commend the government for taking the initiative to explore the legalization of marijuana and we look forward to engaging with the government as this important issue is considered.

For more information, please contact the Canadian Medical Association at info@cma.ca.

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety

Documents

[Image of the document]
National pharmacare in Canada: Getting there from here
https://policybase.cma.ca/link/policy11959

POLICY TYPE
Parliamentary submission

DATE
2016-06-01

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone

https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.
https://policybase.cma.ca/link/policy11814

POLICY TYPE
Response to consultation

DATE
2016-01-20

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents